- Home
- DMII vs PHAT Comparison
DMII vs PHAT Comparison
Compare DMII & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMII | PHAT |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.5M | 759.7M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DMII | PHAT |
|---|---|---|
| Price | $10.16 | $8.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 60.0K | ★ 1.0M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $9.87 | $8.21 |
| 52 Week High | $10.21 | $18.31 |
Technical Indicators
Market Signals| Indicator | DMII | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 38.84 |
| Support Level | $10.12 | N/A |
| Resistance Level | $10.21 | $9.74 |
| Average True Range (ATR) | 0.02 | 0.46 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 55.75 | 9.03 |
Price Performance
Historical ComparisonAbout DMII Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp is a blank check Company.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.